Difesa Capital Management’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Difesa Capital Management’s Portfolio NKGNW Stock Details NKGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-120,623	Closed	-$16.9K	–	82
2023 Q1	$16.9K	Hold	120,623	–	–	0.01%	111
2022 Q4	$10.2K	Buy	120,623 +10,623	+10%	+$892	0.01%	132
2022 Q3	$17K	Hold	110,000	–	–	0.01%	143
2022 Q2	$29K	Hold	110,000	–	–	0.02%	144
2022 Q1	$67K	Hold	110,000	–	–	0.03%	142
2021 Q4	$126K	Buy	+110,000	New	+$112K	0.09%	125

Other funds holding NKGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Difesa Capital Management's NKGNW Position: Q2 2023 in Review

Difesa Capital Management sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q2 2023, closing a stake of 120,623 shares — an estimated $16.9K sold.

Difesa Capital Management first reported a position in NKGNW in Q4 2021 and held it in 6 quarters. The position peaked at $126K in Q4 2021. 35 funds tracked by Wall St. Rank hold NKGNW as of Q2 2023.

Difesa Capital Management reported no remaining NKGen Biotech, Inc. Warrants position as of Q2 2023 after selling out during the quarter.
Difesa Capital Management sold 120,623 NKGen Biotech, Inc. Warrants shares in Q2 2023, an estimated $16.9K.
Difesa Capital Management first reported a position in NKGen Biotech, Inc. Warrants in Q4 2021 and held it in 6 quarters.
Difesa Capital Management's NKGen Biotech, Inc. Warrants position peaked at $126K in Q4 2021.
35 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q2 2023.

Based on Difesa Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.